Literature DB >> 23519917

Influence of the transjugular intrahepatic portosystemic stent on firstline treatment of hepatocellular carcinoma.

Eva Knüppel1, Dominik Bettinger, Wulf Euringer, Robert Thimme, Martin Roessle, Hans Christian Spangenberg, Michael Schultheiβ.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23519917     DOI： 10.1002/hep.26406

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  2 in total

1.  Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.

Authors:  Zhu Wang; Hailong Zhang; He Zhao; Xiaoze Wang; Jiaywei Tsauo; Xuefeng Luo; Xiao Li
Journal:  Diagn Interv Radiol       Date:  2014-11       Impact factor: 2.630

2.  Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS.

Authors:  Wenzhe Fan; Jian Guo; Bowen Zhu; Shutong Wang; Lei Yu; Wanchang Huang; Huishuang Fan; Fuliang Li; Yanqin Wu; Yue Zhao; Yu Wang; Miao Xue; Hongyu Wang; Jiaping Li
Journal:  Eur Radiol       Date:  2021-04-24       Impact factor: 5.315
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.